Thaís Megid: Have You Ever Heard About Negative Hyperselection for EGFR Therapy?
Thaís Megid, Assistant Professor at Université de Sherbrooke, shared a post on LinkedIn:
“Have you ever heard about negative hyperselection for EGFR therapy? Check this review out!
EGFR inhibitors are key in treating RAS/BRAF wild-type metastatic colorectal cancer, but resistance is common. Resistance isn’t random—it’s driven by specific molecular changes (e.g. HER2/MET amplification, PI3K/AKT activation, EGFR mutations).
“Negative hyperselection” uses deep molecular profiling to exclude resistant tumors. Trials show hyperselected patients respond better & live longer than those selected by RAS/BRAF status alone.”
Title: Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Authors: Luís Felipe Leite, Mariana Macambira Noronha, Junior Samuel Alonso de Menezes, Lucas Diniz da Conceição, Luiz F. Costa Almeida, Anelise Poluboiarinov Cappellaro, Marcos Belotto, Tiago Biachi de Castria, Renata D’Alpino Peixoto, Thais Baccili Cury Megid
Read the Full Article.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023